Ascentage Pharma is an integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet …

Jan 24, 2025 · Ascentage co-founder Edward Ming Guo is the company’s largest shareholder with a 17.5% post-IPO stake, according to the prospectus. Takeda owns 7.1% of the company. In …

Jan 27, 2025 · Ascentage's lead development asset is olverembatinib, which is the only approved BCR-ABL1 inhibitor in China for patients with chronic phase or accelerated phase myeloid …

Ascentage Pharma Group International Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts.

Jun 14, 2024 · Ascentage Pharma is investigating olverembatinib in multiple clinical studies in several types of cancer. Olverembatinib has been granted orphan drug designation and Fast …

We are a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs …

Jan 24, 2025 · China-based biotech Ascentage Pharma has raised $126m in a US initial public offering (IPO), marking the first biotech IPO of 2025.

Jul 3, 2024 · Ascentage Pharma (6855.HK) is a fully integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class …

Through state-of-the-art small molecule synthesis, discovery, and development, Ascentage endeavors to engineer innovative targeted therapies that advance the standard of care for …

Jan 24, 2025 · Find the latest Ascentage Pharma Group International (AAPGV) stock quote, history, news and other vital information to help you with your stock trading and investing.